ArticleAlimentary pharmacology & therapeutics2013
The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.
Article in Alimentary pharmacology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Article
- Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).Therapeutics and clinical risk management · 2023Article
- Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.Hepatology international · 2022Article
- Breakthroughs in hepatitis C research: from discovery to cure.Nature reviews. Gastroenterology & hepatology · 2022Review
- Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study.International journal of environmental research and public health · 2021Observational
- Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy.Open forum infectious diseases · 2020Article
- Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications.Visceral medicine · 2019Review
- Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016.BMC infectious diseases · 2018Article
- Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.Oncotarget · 2017Article
- The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.United European gastroenterology journal · 2017Article
- Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.World journal of gastroenterology · 2017Article
- Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.British journal of clinical pharmacology · 2017Review
- Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice.Annals of gastroenterology · 2017Article
- Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.Clinical pharmacokinetics · 2016Review
- Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.European journal of gastroenterology & hepatology · 2014Observational
- IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.World journal of gastroenterology · 2014Article
- Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.Clinical pharmacokinetics · 2014Review
- [New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014].Der Internist · 2014Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug-drug interactions (DDIs) in the treatment of chronic hepatitis C infection became a potential challenge with the introduction of direct-acting anti-virals (DAAs). Both currently approved DAAs, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), are substrates and inhibitors of P-glycoprotein and the cytochrome P450 3A4, which are regularly involved in DDIs.
aimTo analyse the risk for DDIs in patients with chronic HCV genotype 1 infection considered for PI treatment at a tertiary referral centre.
methodsThe first 115 consecutive patients selected for a PI therapy at Hannover Medical School were included. All changes to co-medication before and during PI treatment were documented. Drugs were checked for DDIs with TVR and BOC using DDI websites and the respective prescribing information.
resultsOut-patient medication contained 116 different drugs. Median number of drugs/patient was 2 (range 0-11). The risk for DDIs was substantial for 38% of the drugs affecting 49% of patients. Only 4% of the drugs were strictly contraindicated. DDIs between a PI and drugs newly prescribed during anti-viral therapy were considerable in 42% of the patients. Suspected DDIs were managed by dose adjustments and discontinuation of co-medication in 7% and 21% of the patients respectively.
conclusionsMany patients with chronic HCV genotype 1 infection are affected by potential DDIs if treated with a protease inhibitor, but only in a minority of cases co-medication is strictly incompatible. Overall, the challenge of DDIs is time-consuming, but well manageable by a careful review of the patient's drug chart and monitoring during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.